Tesamorelin 10mg — Vial Spec, Reconstitution Math & COA

Tesamorelin 10mg Vial Overview and Specifications

A 10mg vial of tesamorelin 10mg contains a highly purified, lyophilized cake of a synthetic 44-amino-acid growth-hormone-releasing hormone (GHRH) analog featuring a hexenoyl moiety attached to its N-terminal tyrosine residue. This structural modification enhances metabolic stability against enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) compared to native GHRH(1-44)NH2. Researchers investigating high-throughput cell cultures or long-term rodent cohorts select the 10mg vial format to maintain batch consistency across multiple experimental replicates without introducing inter-vial variance.

In cell culture and animal research models, Tesamorelin acts as a selective agonist at the GHRH receptor (GHRH-R) on pituitary somatotropes. By triggering intracellular adenylate cyclase activity and elevating cyclic AMP (cAMP) levels, the peptide stimulates endogenous synthesis and pulsatile release of growth hormone (GH), which subsequently downstream-regulates insulin-like growth factor 1 (IGF-1) expression in hepatic tissue models. Researchers standardizing assays for tissue repair, lipid metabolism, and somatotropic axis signaling rely on precise lyophilized mass to ensure reproducible dosing concentrations.

If a specific research protocol requires smaller volume runs or alternative packaging configurations, investigators can review our full line of synthetic peptides in the all peptides catalog. PX1 Research provides fully characterizable reference materials formulated for analytical precision and long-term stability in controlled laboratory environments.

Molecular Structure and Mechanism of Action in Preclinical Models

The molecular structure of Tesamorelin comprises the sequence trans-3-hexenoyl-GHRH(1-44) amide, yielding a chemical formula of C221H366N72O67S with a nominal molecular weight of approximately 5195.9 Da. The addition of the trans-3-hexenoyl group at the N-terminus preserves receptor binding affinity while altering the pharmacokinetic profile in blood plasma assays. In vitro radioperfusion assays indicate that this modification slows cleavage by circulating peptidases, thereby extending the biological half-life relative to endogenous GHRH.

Preclinical investigations demonstrate that activation of GHRH-R by Tesamorelin initiates a cascade of intracellular events. G-protein-coupled receptor activation stimulates the Gαs subunit, prompting membrane-bound adenylyl cyclase to convert ATP to cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors such as CREB. This pathway upregulates GH gene transcription and facilitates calcium-dependent exocytosis of stored GH granules. In rodent models of metabolic dysfunction, elevated GH signaling modulates key enzymes involved in lipolysis and hepatic triglyceride accumulation, providing a target model for metabolic research.

Reconstitution Mathematics for 10mg Lyophilized Mass

Reconstituting a 10mg vial requires accurate volumetric measurement of sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the downstream assay. Because 10mg represents a relatively large mass for a single laboratory vial, solvent selection and volumetric concentration planning are critical to avoid solubility saturation or pipetting error.

To achieve target concentrations, researchers can apply standard volumetric formulas. Adding 1.0 mL of diluent to a 10mg lyophilized cake yields a final stock concentration of 10.0 mg/mL (10.0 µg/µL). Adding 2.0 mL of diluent produces a concentration of 5.0 mg/mL (5.0 µg/µL). For assays requiring lower stock density or larger working volumes, adding 3.0 mL of diluent achieves a concentration of approximately 3.33 mg/mL (3.33 µg/µL). Researchers can quickly verify custom concentration parameters and volumetric draw amounts using our online reconstitution calculator.

When introducing diluent to the vial, direct the liquid stream along the interior glass wall rather than directly onto the lyophilized powder. Avoid vigorous vortexing, as shear forces can denature peptide secondary structures. Gently swirl the vial in a smooth circular motion until the cake dissolves completely into a clear, colorless solution free of particulate matter.

Aliquot Planning and Serial Dilution Protocols

To prevent repeated freeze-thaw cycles that can induce peptide aggregation and loss of bioactivity, primary stock solutions should be subdivided into single-use micro-aliquots immediately following reconstitution. Using sterile, low-binding polypropylene microcentrifuge tubes minimizes surface adsorption loss, which is particularly relevant when working with lower concentration working solutions.

For an assay requiring a 100 µg working dose per experimental run, a 10 mg/mL stock solution (reconstituted with 1.0 mL diluent) yields 100 individual micro-aliquots of 10 µL each. If diluted with 2.0 mL of solvent (5.0 mg/mL stock concentration), a 100 µg aliquot requires a 20 µL working volume. Standardizing aliquot volume ensures consistent volumetric delivery during automated or manual micro-pipetting steps in cell-free or cell-based target assays.

When setting up multi-well plates for in vitro receptor binding or messenger RNA expression studies, serial dilutions should be prepared using cold, buffered culture media or phosphate-buffered saline (PBS, pH 7.4) supplemented with 0.1% bovine serum albumin (BSA). The addition of a carrier protein like BSA mitigates non-specific binding of hydrophobic peptide residues to microplate surfaces during incubation periods.

Analytical Verification: Lot-Matched COA, HPLC, and Mass Spectrometry

Quality assurance for high-mass peptides requires multi-tier analytical verification to guarantee identity, purity, and safety from microbial contaminants. PX1 Research subjects every fill batch to independent ISO 17025 accredited laboratory testing. Every lot of tesamorelin 10mg is accompanied by a accessible, lot-matched Certificate of Analysis detailing high-performance liquid chromatography (HPLC) and mass spectrometry (MS) outputs.

Purity assessment via reverse-phase HPLC (RP-HPLC) ensures the primary peak accounts for ≥98% of the total integrated peak area. Mass spectrometry confirms the exact molecular weight matches the theoretical target of ~5195.9 Da, confirming the absence of truncated sequences, deletion peptides, or incomplete synthesis side-products. Additionally, bacterial endotoxin testing (LAL assay) confirms levels remain strictly within established limits (<0.05 EU/mg), preventing confounding inflammatory responses in sensitive cell cultures or animal models. Researchers can review batch testing methodology on our dedicated COA documentation page.

Because manufacturing consistency is vital for long-term experimental validity, researchers conducting comparative study sets across multiple laboratory sites can request specialized bulk documentation and volume allocations through our dedicated wholesale laboratory program.

Comparative Analysis: Tesamorelin vs. CJC-1295 and Ipamorelin

In preclinical studies evaluating GHRH pathway dynamics and somatotropic axis modulation, Tesamorelin is frequently analyzed alongside other secretagogues, including CJC-1295 and Ipamorelin. While all three compounds stimulate growth hormone pathways, their specific receptor targets, binding dynamics, and structural configurations differ significantly.

Tesamorelin functions specifically as a stabilized GHRH-R agonist, mimicking native GHRH signaling while resisting DPP-IV degradation. In contrast, CJC-1295 (both with and without Drug Affinity Complex, or DAC) is a modified GHRH(1-29) fragment designed for extended plasma retention through covalent binding to serum albumin. Meanwhile, Ipamorelin represents a distinct class of secretagogue—a selective growth hormone secretagogue receptor (GHSR-1a) agonist that mimics ghrelin rather than GHRH.

Co-administration or comparative protocols in rodent models show that activating both the GHRH receptor (via Tesamorelin or CJC-1295) and the GHSR-1a receptor (via Ipamorelin) produces a synergistic elevation of GH secretion compared to receptor-monotargeting alone. Understanding these mechanistic distinctions allows researchers to tailor compound selection to specific metabolic, physiological, or gene expression endpoints.

Storage, Handling, and Thermal Stability Protocols

Lyophilized Tesamorelin is stable at room temperature for brief periods during transit, but long-term laboratory storage requires controlled thermal management. Upon receipt, desiccated vials should be stored at -20°C in a manual defrost freezer, protected from light exposure. Under these conditions, the lyophilized peptide maintains structural integrity and nominal purity for up to 24 months.

Following reconstitution with sterile bacteriostatic water, liquid stock solutions must be stored under refrigeration at 2°C to 8°C. At refrigerated temperatures, reconstituted solutions remain stable for up to 28 days due to the preservative action of benzyl alcohol. If reconstituted with unpreserved sterile water or saline, the solution must be used immediately or micro-aliquoted and stored at -80°C to prevent microbial growth and rapid hydrolysis.

Freeze-thaw cycles must be rigorously avoided. Repeated phase transitions induce ice crystal formation, which causes mechanical shearing of peptide chains, leading to aggregation and loss of specific biological activity. Maintain strict log records of storage temperatures, reconstitution dates, and aliquot usage in accordance with standard operating procedures.

Selecting Formulations: Evaluating 10mg vs. 2mg and 5mg Options

Determining whether a 10mg vial configuration or smaller fill sizes (such as 2mg or 5mg vials) are optimal depends on the scale and duration of the planned research study. The 10mg mass format offers maximum economic efficiency and lot uniformness for large-scale animal studies involving daily dosing schedules over several weeks.

For small-scale exploratory experiments, single-cell assays, or pilot binding affinity studies where total peptide consumption is low, smaller fill sizes may be preferable to minimize the duration that reconstituted solutions remain in liquid storage. Using smaller vials reduces the potential for cumulative degradation or contamination risk over extended experimental timelines.

Regardless of the vial size selected, maintaining uniform dilution metrics, solvent purity, and cold-chain handling protocols ensures valid, reproducible data across all experimental groups. Additional technical literature and compound profiles are available in our centralized peptide research hub.

PX1 Research Quality Standards and Manufacturing Controls

PX1 Research manufactures synthetic peptides in state-of-the-art facilities located within the United States. All production operations follow strict Good Manufacturing Practice (GMP) guidelines to eliminate cross-contamination, volatile solvent residues, and trace heavy metal impurities.

Synthetic peptide chains are synthesized using solid-phase peptide synthesis (SPPS) technology, followed by multi-stage liquid chromatography purification. Each lot undergoes rigorous vacuum lyophilization to achieve low moisture content (<3%), ensuring extended shelf-life and rapid dissolution upon reconstitution. Every batch shipped from our CA and AZ facilities includes lot-matched analytical documentation to guarantee laboratory compliance and research integrity.